News

Multimedia

Conferences

Publications

Brand Insights

Resources

Sustainability
DE&I
Pandemic
Finance
Legal
Technology
Regulatory
Global
Pricing
Strategy
R&D/Clinical Trials
Opinion
Executive Roundtable
Sales & Marketing
Executive Profiles
Leadership
Market Access
Patient Engagement
Supply Chain
Industry Trends

$10 Sovaldi on Sale in Bangladesh

March 12, 2015

By News Update

Article

March 12. 2015.

Incepta Pharmaceuticals has introduced a version of Gilead's hepatitis C treatment, Sovaldi, at $10 a pill in Bangladesh, Bloomberg reports. The drug sells for $1,000 a pill in the United States.

Incepta doesn’t have a license from Gilead - Bangladesh is one country, along with Thailand, Malaysia and Morocco, where Sovaldi isn’t patented - but the company is marketing the treatment at about $900 for 12 weeks, the same price as Gilead is offering its branded version of the drug in India.

Bloomberg.

Related Content

AI in Pharma: Where, When, and How Executives are Considering it

Gaugarin Oliver

November 19th 2024

Article

As skepticism surrounding AI fades, pharma industry execs are ready to embrace the technology.

Drilling in on Disease Hallmarks: New Tricks to Solve Age-Old Problems

Mike Hollan

November 15th 2024

Article

Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, discusses how AI is being used to find new ways to treat age-related conditions.

The Leap Forward: Practical Gains for Pharma AI Use

Bianca Anghelina;Helen Merianos;Ruth Beadle

November 14th 2024

Article

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.